Barclays Capital Begins Covering UDG Healthcare PLC (LON:UDG) Stock. “Shares to Hit GBX 875.00”

May 17, 2018 - By Christine McCrea

UDG Healthcare plc (LON:UDG) Logo

Why Has Barclays Capital Given UDG Healthcare PLC (LON:UDG) a GBX 875.00 Price Target

Barclays Capital analyst initiated coverage on UDG Healthcare PLC (LON:UDG) with a GBX 875.00 target price and Equal weight rating. The target price suggests a potential downside of -5.86 % from company’s last price.

UDG Healthcare plc (LON:UDG) Ratings Coverage

Among 8 analysts covering UDG Healthcare PLC (LON:UDG), 3 have Buy rating, 1 Sell and 4 Hold. Therefore 38% are positive. UDG Healthcare PLC has GBX 1100 highest and GBX 765 lowest target. GBX 869.50’s average target is -6.30% below currents GBX 928 stock price. UDG Healthcare PLC had 20 analyst reports since November 28, 2017 according to SRatingsIntel. The firm earned “Hold” rating on Tuesday, January 30 by Liberum Capital. The rating was maintained by Peel Hunt with “Buy” on Tuesday, May 1. The company was maintained on Tuesday, November 28 by N+1 Singer. On Tuesday, November 28 the stock rating was maintained by Peel Hunt with “Add”. The stock of UDG Healthcare plc (LON:UDG) has “Reduce” rating given on Tuesday, January 30 by Numis Securities. The firm has “Hold” rating given on Monday, December 4 by Jefferies. On Wednesday, April 4 the stock rating was maintained by Peel Hunt with “Add”. Peel Hunt maintained it with “Add” rating and GBX 880 target in Thursday, December 7 report. On Wednesday, February 7 the stock rating was maintained by N+1 Singer with “Hold”. The stock has “Add” rating by Peel Hunt on Thursday, February 1.

The stock increased 0.22% or GBX 2 during the last trading session, reaching GBX 928. About 847,545 shares traded. UDG Healthcare plc (LON:UDG) has 0.00% since May 17, 2017 and is . It has underperformed by 11.55% the S&P500.

UDG Healthcare plc, together with its subsidiaries, provides advisory, communication, commercial, clinical, and packaging services to the healthcare industry in the Republic of Ireland, the United Kingdom, North America, and internationally. The company has market cap of 2.31 billion GBP. The firm operates through three divisions: Ashfield, Sharp, and Aquilant. It has a 32.22 P/E ratio. The Ashfield segment offers commercialization services for the pharmaceutical and healthcare industry in the areas of advisory, communications, and commercial and clinical services.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: